Author(s): Zhen C; Wang L; Feng Y; Whiteway M; Hang S; Yu J; Lu H; Jiang Y;

Candidiasis, which presents a substantial risk to human well-being, is frequently treated with azoles. However, drug-drug interactions caused by azoles inhibiting the human CYP3A4 enzyme, together with increasing resistance of Candida species to azoles, represent serious issues with this class of drug, making it imperative to develop innovative antifungal ...

Article GUID: 38995235

Author(s): Li W; Feng Y; Feng Z; Wang L; Whiteway M; Lu H; Jiang Y;

Fluconazole (FLC) is extensively employed for the prophylaxis and treatment of invasive fungal infections (IFIs). However, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance towards it. Consequently, converting FLC into a fungicidal agent using adjuvants assumes significance to circumvent FLC resistance and the perpetua ...

Article GUID: 38929106

Author(s): Feng Y; Lu H; Whiteway M; Jiang Y;

Fluconazole (FLC) tolerant phenotypes in Candida species contribute to persistent candidemia and the emergence of FLC resistance. Therefore, making FLC fungicidal and eliminating FLC tolerance are important for treating invasive fungal diseases (IFDs) caused by Candida species. However, the mechanisms of FLC tolerance in Candida species remain to be fully ...

Article GUID: 37918789

Author(s): Lu H; Hong T; Jiang Y; Whiteway M; Zhang S;

Candidiasis is an infection caused by fungi from a Candida species, most commonly Candida albicans. C. albicans is an opportunistic fungal pathogen typically residing on human skin and mucous membranes of the mouth, intestines or vagina. It can cause a wide variety of mucocutaneous barrier and systemic infections; and becomes a severe health problem in HI ...

Article GUID: 37307922

Author(s): Lu H; Li W; Whiteway M; Wang H; Zhu S; Ji Z; Feng Y; Yan L; Fang T; Li L; Ni T; Zhang X; Lv Q; Ding Z; Qiu L; Zhang D; Jiang Y;

Fluconazole (FLC) is widely used to prevent and treat invasive fungal infections. However, FLC is a fungistatic agent, allowing clinical FLC-susceptible isolates to tolerate FLC. Making FLC fungicidal in combination with adjuvants is a promising strategy to avoid FLC resistance and eliminate the ...

Article GUID: 36475771

Author(s): Li W; Shrivastava M; Lu H; Jiang Y;

Increased morbidity and mortality of candidiasis are a notable threat to the immunocompromised patients. At present, the types of drugs available to treat C. albicans infection are relatively limited. Moreover, the emergence of antifungal drug resistance of C. albicans makes the treatment of C. albicans infection more difficult. The calcium-calcineurin si ...

Article GUID: 33989979

Author(s): Lu H, Shrivastava M, Whiteway M, Jiang Y

Fluconazole has characteristics that make it widely used in the clinical treatment of C. albicans infections. However, fluconazole has only a fungistatic activity in C. albicans, therefore, in the long-term treatment of C. albicans infection with fluconazole, C. albicans has the potential to acquire fluconazole resistance. A promising approach to increase ...

Article GUID: 33587857

Author(s): Tamming RJ, Dumeaux V, Jiang Y, Shafiq S, Langlois L, Ellegood J, Qiu LR, Lerch JP, Bérubé NG

Cell Rep. 2020 Jun 30;31(13):107838 Authors: Tamming RJ, Dumeaux V, Jiang Y, Shafiq S, Langlois L, Ellegood J, Qiu LR, Lerch JP, Bérubé NG

Article GUID: 32610139